Kiniksa Pharmaceuticals International vs Nasus Pharma
KNSA and NSRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KNSA and NSRX compare
Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −0.47% at Nasus Pharma.
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 6 for Nasus Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KNSA | NSRX |
|---|---|---|
| Size and price | ||
| Market cap | $15.1B | – |
| Share price | $96.33 | $2.87 |
| Change, 1 year | 137% | −62.2% |
| Change, 5 years | 690% | – |
| Beta (5Y) | 0.31 | 1.33 |
| Employees | 366 | – |
| StockData Score | ||
| Total score | 14 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 0 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 74.1× | – |
| P/S | 16.0× | – |
| P/B | 21.3× | – |
| EV/EBITDA | 110× | – |
| P/FCF | 76.8× | – |
| FCF yield | 1.3% | – |
| Fair value | $17.17 | – |
| Margin of safety | −461% | – |
| Growth | ||
| Revenue growth (TTM) | 58.2% | – |
| Net income growth (TTM) | 205% | – |
| EPS growth (TTM) | 189% | – |
| Profitability | ||
| Gross margin | 90.2% | – |
| Operating margin | 13.8% (better) | −0.40% |
| Net margin | 11.6% (better) | −0.47% |
| FCF margin | 20.8% (better) | −0.40% |
| Return on equity | 17.6% (better) | −175% |
| Return on invested capital | 60.2% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.91 | 8.77 (better) |
| Altman Z-score | 34.82 | – |
| Piotroski F-score | 8 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 29.9% | 23.9% |
| Held by insiders | 5.1% | 59.3% |
| Insider net buying, 12 months | −$122M | $61.8K (better) |
| Short interest, % of float | 2.9% | 1.9% |
Go deeper
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
- NSRX stock overview
- NSRX income statement
- NSRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.